Céline Namour
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, COVID-19 Clinical Research Studies, Lung Cancer Treatments and Mutations, COVID-19 and healthcare impacts, SARS-CoV-2 and COVID-19 Research
Most-Cited Works
- → Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer(2019)170 cited
- → Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses(2021)62 cited
- → Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study(2022)26 cited
- → Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors(2020)17 cited
- → Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates(2024)12 cited
- → Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses(2021)8 cited
- → Patients avec cancers thoraciques et COVID-19 : au cœur de la tempête(2021)1 cited
- → TP53 mutations as predictor of response and longer survival under immune checkpoint inhibitors in advanced non-small cell lung cancer(2018)1 cited
- → Supplementary Data1 from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates(2025)
- → Data from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates(2025)